Navigation Links
Bone cancer treatment ineffective, despite promising laboratory data
Date:11/10/2008

San Francisco, Calif. November 10, 2008 Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory. Treatment of Ewing sarcoma that relapses is difficult. A new study published in Pediatric Blood & Cancer evaluated a phase II clinical trial of a potential new treatment approach for relapsed Ewing sarcoma using cytarabine.

Ten patients were treated. While one patient's tumor stayed stable in size for approximately 4 months while receiving the drug, none of the ten patients had smaller tumors after treatment with cytarabine. This result is disappointing since laboratory studies indicated that cytarabine might be an effective drug for these patients. In addition, these patients with Ewing sarcoma developed lower blood counts than expected from these doses of cytarabine. The fact that the drug was not found to be effective is yet another example in which laboratory data do not always translate into success in treating patients.

"Cytarabine is not an effective agent for patients with Ewing sarcoma and this drug should be used with caution in heavily pretreated patients with solid tumors due to the significant impact of the drug on blood counts," says Steven DuBois, co-author of the study. This study demonstrates the difficulties of extending promising therapeutic targets observed in the laboratory to effective treatments in patients. It also emphasizes the need for more predictive preclinical models.


'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Page: 1

Related medicine news :

1. Karmanos Cancer Institute Seeks Breast Cancer Patients to Participate in a New Drug Trial
2. Sexual intimacy and breast cancer survivors: New research
3. Cancer drugs my build and not tear down blood vessels
4. Cost of treating colorectal cancer can vary by thousands per patient
5. Barry Manilow Brings Valentines and Music to New York With Concert to Raise Funds for Breast Cancer Research
6. AMA Immediate Past President Ron Davis Loses Battle With Cancer, Leaves Enduring AMA and Public Health Legacy
7. ESF workshop makes major advance in cancer radiotherapy
8. More People Living Longer After Cancer Diagnosis
9. Researchers find predictive tests and early treatment delay progression of blood cell cancer
10. Negative Cancer Messages Backfire With Blacks
11. Lung Cancer Alliance-Georgia Issues Third Annual State-Specific Report Card on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... Dec. 8, 2016 Australia Glaucoma Surgery ... GlobalData,s new report, "Australia Glaucoma Surgery Devices Market ... the Australia Glaucoma Surgery Devices market. The report ... (in units) and average prices (USD) within market ... also provides company shares and distribution shares data ...
(Date:12/8/2016)... -- KEY FINDINGS The global medical lifting ... reasons for growth of the medical lifting sling market ... diseases, high recovery cost of injuries and government initiatives ... sling refers to an assistive device that helps caregiver ... to the lift and hold the patient. It is ...
Breaking Medicine Technology: